Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Fluvoxamine Extended-release Generic Name & Formulations
Legal Class
Rx
General Description
Fluvoxamine maleate 100mg, 150mg; ext-rel caps.
Pharmacological Class
SSRI.
How Supplied
Contact supplier
Manufacturer
Fluvoxamine Extended-release Indications
Indications
Obsessive-compulsive disorder.
Fluvoxamine Extended-release Dosage and Administration
Adult
Swallow whole. ≥18yrs: initially 100mg once daily at bedtime; may increase in 50mg increments at 1-week interval; range 100–300mg/day; max 300mg/day. Elderly, hepatic impairment: initially 100mg and titrate slowly.
Children
Not established.
Fluvoxamine Extended-release Contraindications
Contraindications
Concomitant alosetron, tizanidine, pimozide, thioridazine, ramelteon. During or within 14 days of MAOIs; do not start an MAOI during or within 14 days of fluvoxamine. Concomitant linezolid, IV methylene blue.
Fluvoxamine Extended-release Boxed Warnings
Boxed Warning
Suicidality and antidepressants.
Fluvoxamine Extended-release Warnings/Precautions
Warnings/Precautions
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults; monitor for clinical worsening or unusual changes. Screen for bipolar disorder. Monitor for serotonin syndrome; discontinue if occurs. History of seizures (discontinue if occurs), mania/hypomania. ECT. Cardiovascular disease. Liver dysfunction. Angle-closure glaucoma. Conditions that affect metabolism or hemodynamic response. Hyponatremia (esp. in elderly). Sexual dysfunction. Reduced activity of CYP2D6. Reevaluate periodically. Write ℞ for smallest practical amount. Avoid abrupt cessation. Elderly. Labor & delivery. Pregnancy (esp. during 3rd trimester). Nursing mothers: monitor infants.
Fluvoxamine Extended-release Pharmacokinetics
See Literature
Fluvoxamine Extended-release Interactions
Interactions
See Contraindications. Prolongation of QT interval with pimozide, thioridazine. Avoid alcohol. Increased risk of serotonin syndrome with other serotonergic drugs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, amphetamines, St. John's wort, linezolid, IV methylene blue; monitor. Potentiates diazepam (not recommended), triazolam and alprazolam (reduce their doses by at least ½), midazolam, theophylline (reduce its dose by ⅔ and monitor), warfarin, carbamazepine, tricyclic antidepressants (reduce their doses and monitor), propranolol, metoprolol (reduce their doses), clozapine, methadone, tacrine. Caution with drugs that inhibit CYP2D6 (eg, quinidine) or CYP3A4, phenytoin, diltiazem. Increased risk of bleeding with concomitant NSAIDs, aspirin, warfarin, and others that affect coagulation. Monitor mexiletine levels. Smokers may have increased metabolism.
Fluvoxamine Extended-release Adverse Reactions
Adverse Reactions
Abnormal ejaculation, anorexia, anorgasmia, asthenia, diarrhea, nausea, somnolence, sweating, tremor, anxiety, decreased libido, myalgia, pharyngitis, vomiting, dyspepsia, dizziness, insomnia, yawning.
Fluvoxamine Extended-release Clinical Trials
See Literature
Fluvoxamine Extended-release Note
Notes
Formerly known under the brand name Luvox CR.
Fluvoxamine Extended-release Patient Counseling
See Literature
